BR112013008211A8 - Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende - Google Patents

Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende

Info

Publication number
BR112013008211A8
BR112013008211A8 BR112013008211A BR112013008211A BR112013008211A8 BR 112013008211 A8 BR112013008211 A8 BR 112013008211A8 BR 112013008211 A BR112013008211 A BR 112013008211A BR 112013008211 A BR112013008211 A BR 112013008211A BR 112013008211 A8 BR112013008211 A8 BR 112013008211A8
Authority
BR
Brazil
Prior art keywords
salts
cocrystals
composition including
ccr3 inhibitors
ccr3
Prior art date
Application number
BR112013008211A
Other languages
English (en)
Other versions
BR112013008211A2 (pt
BR112013008211B1 (pt
Inventor
Frank Markus
Haeberle Hans
Henry Manuel
Pachur Thorsten
Santagostino Marco
Stertz Uwe
Trebing Thomas
Werthmann Ulrike
Original Assignee
Boehringer Ingelheim Int
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Alkahest Inc filed Critical Boehringer Ingelheim Int
Priority to BR122021010665-7A priority Critical patent/BR122021010665B1/pt
Publication of BR112013008211A2 publication Critical patent/BR112013008211A2/pt
Publication of BR112013008211A8 publication Critical patent/BR112013008211A8/pt
Publication of BR112013008211B1 publication Critical patent/BR112013008211B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COCRISTAIS E SAIS DE INIBIDORES DE CCR3. Esta invenção refere-se a cocritais e a sais de inibidores de CCR3 de fórmulas (1) a composições farmacêuticas contendo os mesmos, e a métodos de utilização dos mesmos como agentes para o tratamento e/ou a prevenção de doenças relacionadas com o receptor CCR3.
BR112013008211-9A 2010-10-07 2011-10-06 Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende BR112013008211B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021010665-7A BR122021010665B1 (pt) 2010-10-07 2011-10-06 Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10186901 2010-10-07
EP10186901.4 2010-10-07
PCT/EP2011/067437 WO2012045803A1 (en) 2010-10-07 2011-10-06 Co-crystals and salts of ccr3-inhibitors

Publications (3)

Publication Number Publication Date
BR112013008211A2 BR112013008211A2 (pt) 2016-06-21
BR112013008211A8 true BR112013008211A8 (pt) 2017-10-10
BR112013008211B1 BR112013008211B1 (pt) 2021-08-24

Family

ID=44741339

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013008211-9A BR112013008211B1 (pt) 2010-10-07 2011-10-06 Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BR122021010665-7A BR122021010665B1 (pt) 2010-10-07 2011-10-06 Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122021010665-7A BR122021010665B1 (pt) 2010-10-07 2011-10-06 Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende

Country Status (36)

Country Link
US (3) US8742115B2 (pt)
EP (1) EP2625174B1 (pt)
JP (1) JP5794713B2 (pt)
KR (3) KR102163874B1 (pt)
CN (1) CN103140486B (pt)
AP (1) AP3268A (pt)
AR (1) AR083353A1 (pt)
AU (1) AU2011311530B2 (pt)
BR (2) BR112013008211B1 (pt)
CA (1) CA2807255C (pt)
CL (1) CL2013000488A1 (pt)
CO (1) CO6710910A2 (pt)
CY (1) CY1116168T1 (pt)
DK (1) DK2625174T3 (pt)
EA (1) EA029097B1 (pt)
EC (1) ECSP13012600A (pt)
ES (1) ES2535264T3 (pt)
GE (1) GEP20166488B (pt)
HR (1) HRP20150419T1 (pt)
HU (1) HUE024540T2 (pt)
IL (1) IL224269A (pt)
MA (1) MA34545B1 (pt)
ME (1) ME02040B (pt)
MX (1) MX2013003785A (pt)
MY (1) MY167898A (pt)
NZ (1) NZ605827A (pt)
PE (1) PE20140188A1 (pt)
PL (1) PL2625174T3 (pt)
PT (1) PT2625174E (pt)
RS (1) RS53858B1 (pt)
SG (1) SG188949A1 (pt)
SI (1) SI2625174T1 (pt)
TW (1) TWI546294B (pt)
UA (1) UA109290C2 (pt)
UY (1) UY33655A (pt)
WO (1) WO2012045803A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
CN110650740A (zh) * 2017-04-05 2020-01-03 万能溶剂有限公司 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
EP3694514A4 (en) * 2017-10-13 2021-07-07 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF PRURITUS, XEROSIS AND ASSOCIATED DISEASE USING CCR3 INHIBITORS
AU2019271122A1 (en) 2018-05-15 2020-11-12 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
MX2021002967A (es) * 2018-09-26 2021-08-11 Alkahest Inc Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3.
US20230312697A1 (en) * 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
WO1999037619A1 (en) 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
EP1052992A1 (en) 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CN100436449C (zh) * 2001-11-29 2008-11-26 先灵公司 作为ccr5-拮抗剂用于治疗aids和相关的hiv感染的药用盐的制备
EP1596869B1 (en) * 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
MXPA06004304A (es) 2003-10-24 2006-06-05 Hoffmann La Roche Antagonistas del receptor ccr-3.
CN1946402A (zh) 2004-02-05 2007-04-11 先灵公司 用作ccr3拮抗剂的哌啶衍生物
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US20090124636A1 (en) 2006-04-12 2009-05-14 Pfizer Inc. Chemical compounds
KR101176697B1 (ko) * 2006-04-20 2012-08-23 에프. 호프만-라 로슈 아게 케모카인 수용체의 다이아제판 유도체 조절자
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
US8742115B2 (en) 2014-06-03
ES2535264T3 (es) 2015-05-07
SG188949A1 (en) 2013-05-31
EA201300436A8 (ru) 2018-01-31
US9233950B2 (en) 2016-01-12
GEP20166488B (en) 2016-06-10
PE20140188A1 (es) 2014-02-26
CA2807255C (en) 2018-11-13
JP5794713B2 (ja) 2015-10-14
NZ605827A (en) 2015-09-25
BR112013008211A2 (pt) 2016-06-21
US20150105371A1 (en) 2015-04-16
TWI546294B (zh) 2016-08-21
AU2011311530B2 (en) 2015-04-09
AU2011311530A1 (en) 2013-01-31
PL2625174T3 (pl) 2015-06-30
CA2807255A1 (en) 2012-04-12
TW201305134A (zh) 2013-02-01
CL2013000488A1 (es) 2013-07-05
SI2625174T1 (sl) 2015-03-31
HRP20150419T1 (hr) 2015-05-22
KR20130118313A (ko) 2013-10-29
ME02040B (me) 2015-05-20
KR20190104645A (ko) 2019-09-10
AP2013006679A0 (en) 2013-01-31
BR112013008211B1 (pt) 2021-08-24
PT2625174E (pt) 2015-03-09
MY167898A (en) 2018-09-26
HUE024540T2 (hu) 2016-01-28
EA029097B1 (ru) 2018-02-28
RS53858B1 (en) 2015-08-31
IL224269A (en) 2017-08-31
CO6710910A2 (es) 2013-07-15
WO2012045803A1 (en) 2012-04-12
AP3268A (en) 2015-05-31
CN103140486A (zh) 2013-06-05
ECSP13012600A (es) 2013-07-31
UY33655A (es) 2012-04-30
EP2625174A1 (en) 2013-08-14
US20120264729A1 (en) 2012-10-18
MA34545B1 (fr) 2013-09-02
CY1116168T1 (el) 2017-02-08
EP2625174B1 (en) 2015-01-21
JP2013542207A (ja) 2013-11-21
DK2625174T3 (da) 2015-02-02
MX2013003785A (es) 2013-06-05
CN103140486B (zh) 2016-08-03
KR102163874B1 (ko) 2020-10-12
KR20180005717A (ko) 2018-01-16
AR083353A1 (es) 2013-02-21
EA201300436A1 (ru) 2013-08-30
UA109290C2 (uk) 2015-08-10
US20140135307A1 (en) 2014-05-15
KR102239690B1 (ko) 2021-04-13
BR122021010665B1 (pt) 2022-03-15
KR101844215B1 (ko) 2018-04-03

Similar Documents

Publication Publication Date Title
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
BR112015007083A2 (pt) inibidores de histona demetilases
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112014006297A2 (pt) inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica
BR112013016595A2 (pt) inibidores de neprilisina
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
CR20110270A (es) Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
BR112013011441A2 (pt) composto, composição farmacêutica, e, uso de um composto
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ALKAHEST, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2011, OBSERVADAS AS CONDICOES LEGAIS.